Navigation Links
Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Date:12/8/2011

HAYWARD, Calif., Dec. 8, 2011 /PRNewswire/ -- Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would benefit from reducing their sUA values below 5 or even 4 mg/dL because this would result in more rapid dissolution of their UA crystal deposits. Most patients treated with currently marketed xanthine oxidase inhibitors (allopurinol or febuxostat) alone do not reach these goals. Arhalofenate, Metabolex's lead product candidate for the treatment of hyperuricemia and gout, is a uricosuric agent that could provide additional sUA lowering when used in combination with xanthine oxidase inhibitors and be a treatment option for patients with tophaceous gout.

Clinical Study of Combination of Arhalofenate and Febuxostat

This study was an open label clinical pharmacology study on a single cohort of 11 gout patients with sUA levels of at least 8 mg/dL (mean of 9.1 mg/dL). The primary goal of the study was to assess the response rate (percentage of patients reaching goal) for the sUA targets of 5 and 4 mg/dL when treated in combination with the highest dose (80 mg) of febuxostat approved in the US and two doses (400 and 600 mg) of arhalofenate. The patients were either treatment naive or had discontinued uric acid lowering therapies for a period prior to entering the study. All patients received colchicine throughout the study for flare prophylaxis. After a two week run-in period for sUA stabilization, all 11 patients received febuxostat (80 mg) for one week. Subsequently, patients were administered 400 mg of arhalofenate for two weeks followed by up-titration of arhalo
'/>"/>

SOURCE Metabolex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Metabolex Announces Election of Kurt von Emster to Board of Directors
4. Metabolex Initiates Phase 2 Trial of Arhalofenate
5. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
6. Metabolex Gout Program Recognized in Windhovers Top 10 Most Interesting Projects to Watch
7. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
8. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Anesiva Announces Second Quarter 2008 Financial Results and Update
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Discovery Laboratories, Inc. (Nasdaq: ... awarded a Phase II Small Business Innovation Research ... from the National Institute of Allergy and Infectious ... (NIH) to support the development of the Company,s ... countermeasure to mitigate acute and chronic/late-phase radiation-induced lung ...
(Date:10/1/2014)... -- Pfanstiehl has announced the launch of cGMP-produced, ... USA under ICH Q7 ... playing a key role in protein glycosylation.  Now, ... media supplementation with mannose can improve overall culture ... Dr. Christopher Wilcox , VP, Business Development ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... 5 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the Natixis,Bleichroeder Hidden Gems Conference ... presentation will begin at 2:45 p.m. Eastern Time in ... To access the live audio webcast or the subsequent ...
... Sigma-Aldrich Corporation,(Nasdaq: SIAL ), will hold ... on Wednesday, October 24, 2007, at 11:00 a.m. ... is being webcast by Thomson/CCBN and can be ... . The webcast is also being distributed ...
Cached Biology Technology:VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Sigma-Aldrich Corporation's 3rd Quarter 2007 Earnings Conference Call 2
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... face a suite of perilous threats in today,s ... and climate change, fragile coral ecosystems are disappearing ... trend, some species of corals surrounding the island ... protector in their tropical environment: coral guard-crabs. New ... Smithsonian Marine Station scientist Seabird McKeon and the ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... Assistant Professor of Pharmacology at LSU Health Sciences Center ... $1.2 million Research Project (RO1) grant by the National ... of Health. The 5-year grant will support his research ... brain in regulating blood pressure and the development of ...
... in Spanish . The journal " Science ... August the results of a detailed research work about the ... years. The study has been carried out with the participation ... Panama., The results obtained prove that the main concentrations of ...
... amounts of data are being generated in health care, ... these massive and unstructured data sets has proven cumbersome ... and visual analytics is helping sift through such mountains ... of a picture. The Georgia Institute of Technology ...
Cached Biology News:LSUHSC's Lazartigues awarded $1.2 million grant 2Fossil and molecular evidence reveals the history of major marine biodiversity hotspots 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: